RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS

被引：0
|
作者：
KIRWAN, JR [1 ]
CURREY, HLF [1 ]
机构：
[1] LONDON HOSP, LONDON E1 1BB, ENGLAND
来源：
CLINICS IN RHEUMATIC DISEASES | 1983年 / 9卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：581 / 599
页数：19
相关论文
共 50 条
  • [31] Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
    Bianchi, Gerolamo
    Carletto, Antonio
    Epis, Oscar Massimiliano
    Scioscia, Crescenzio
    Semeraro, Angelo
    Bianchino, Laura
    Bazzichi, Laura
    Lapadula, Giovanni
    Sinigaglia, Luigi
    Lo Monaco, Andrea
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1045 - S1046
  • [32] The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients
    Shahabi, Ahva
    Shafrin, Jason
    Zhao, Lauren
    Green, Sarah
    Curtice, Tammy
    Marshall, Alexander
    Paul, Damemarie
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 350 - 358
  • [33] A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis
    Sen, Rouhin
    Riofrio, Maria
    Singh, Jasvinder A.
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (06) : 687 - 714
  • [34] IMMUNOGENICITY OF SUBCUTANEOUS AND INTRAVENOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Genovese, Mark C.
    Ogata, Atsushi
    Nomura, Akira
    Bao, Min
    Hitraya, Elena
    Lacey, Stuart
    Burmester, Gerd R.
    RHEUMATOLOGY, 2016, 55 : 92 - 93
  • [35] Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
    Ahmad Y. Abuhelwa
    Ashley M. Hopkins
    Michael J. Sorich
    Susanna Proudman
    David J. R. Foster
    Michael D. Wiese
    Scientific Reports, 10
  • [36] Prescribing patterns and clinical outcomes of biological disease-modifying anti-rheumatic drugs for rheumatoid arthritis in Spain
    Martinez-Mugica, C.
    Manso, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (15) : 8177 - 8184
  • [37] Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
    Abuhelwa, Ahmad Y.
    Hopkins, Ashley M.
    Sorich, Michael J.
    Proudman, Susanna
    Foster, David J. R.
    Wiese, Michael D.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [38] Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis
    Hodkinson, B.
    Musenge, E.
    Ally, M.
    Meyer, P. W. A.
    Anderson, R.
    Tikly, M.
    CLINICAL RHEUMATOLOGY, 2012, 31 (04) : 613 - 619
  • [39] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Roy Fleischmann
    Clinical Rheumatology, 2021, 40 : 4369 - 4372
  • [40] Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis
    Rodriguez-Rodriguez, L.
    Jover-Jover, J. A.
    Fontsere, O.
    Pena-Blanco, R. C.
    Leon, L.
    Fernandez-Gutierrez, B.
    Abasolo, L.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2013, 42 (06) : 433 - 436
12345